Ankylosing Spondylitis Treatment Report
www.AnkylosingSpondylitisTreatmentReport.com
https://www.biospace.com/article/releases/cimzia-and-174-certolizumab-pegol-now-approved-in-canada-for-the-treatment-of-non-radiographic-axial-spondyloarthritis/
CIMZIA (certolizumab pegol) Now Approved in Canada for the Treatment of Non-Radiographic Axial Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT03215277?type=Intr&cond=ankylosing+spondylitis&phase=0124&lupd_s=12%2F23%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
DESCRIPTION:
Condition: Ankylosing Spondylitis
Interventions: Drug: Bimekizumab; Drug: Certolizumab pegol; Other: Placebo
Sponsor: UCB Biopharma S.P.R.L.
Active, not recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT03215277
FIRST POSTED:
Wed, 12 Jul 2017 12:00:00 EDT
LAST UPDATE POSTED:
01/06/20 07:53AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03215277?type=Intr&cond=ankylosing+spondylitis&phase=0124&lupd_s=12%2F23%2F2019&lupd_d=14&sort=nwst
